Gilde Healthcare sells RAD-x to a consortium of Swiss Life Asset Managers and Vesper Infrastructure Fund I - Gilde Healthcare

Gilde Healthcare sells RAD-x to a consortium of Swiss Life Asset Managers and Vesper Infrastructure Fund I

18 maart 2024
Utrecht (the Netherlands)

Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare”), a specialized healthcare investor, has reached a binding agreement to sell its majority stake in RAD-x to a consortium of Swiss Life Asset Managers and Vesper Next Generation Infrastructure Fund I.

Gilde Healthcare invested in and, together with the founders, set-up RAD-x in 2016. Since its inception and partnership with the first diagnostic imaging center, RAD-x has successfully grown into a leading Pan-European operator with 23 sites, more than 130 doctors and 750 staff across Germany and Switzerland, now performing more than 400,000 examinations annually. Historically, RAD-X has acted as one of the main market consolidators and remains well positioned to further broaden its radiology platform across Europe under the new ownership. The consortium will support RAD-x’s growth ambitions through a significant growth plan aimed at expanding its current footprint in its existing as well as new markets. The transaction is subject to customary regulatory approvals and is expected to close mid 2024.

Jasper van Gorp, Managing Partner of Gilde Healthcare, said: “We are proud of what we achieved in the past years, creating a leading platform in the diagnostic imaging space by consistently expanding the business. We would like to thank RAD-x management and staff for a great cooperation and wish them all the best for their further growth plans together with the new owners.”

Arthur Vogt and Fabian Groß, Co-CEOs of RAD-x, said: “We are excited to welcome Swiss Life Asset Managers and Vesper Next Generation Infrastructure Fund I as our new partners who share our vision of high quality and best available diagnostic care for our patients as well as a successful future for our amazing employees. On behalf of the entire RAD-x team, we would like to thank the team at Gilde Healthcare for their support since the beginning of this exciting journey.” 

Lincoln International (M&A), EY (financial and tax), Willkie Farr & Gallagher (tax), L.E.K. Consulting (commercial), LUPP+Partner (legal), Ebner Stolz (legal) and Dentons France (legal) have been acting as advisors to Gilde Healthcare.

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Private Equity and Venture&Growth. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com

About RAD-x
Founded in 2016 and headquartered in Mannheim, Germany, RAD-x is one of the leading diagnostic imaging providers in Germany and Switzerland. RAD-X has grown from a single clinic to one of the largest diagnostic imaging platforms in the region, with 23 centres across Germany and Switzerland. Through its continued focus on technology and innovation, RAD-x remains at the forefront of diagnostic imaging as it provides high quality and reliable diagnostic services to its patients. (www.rad-x.eu)

Gilde Healthcare sells RAD-x to a consortium of Swiss Life Asset Managers and Vesper Infrastructure Fund I

Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare”), a specialized healthcare investor, has reached a binding agreement to sell its majority stake in RAD-x to a consortium of Swiss Life Asset Managers and Vesper Next Generation...
18 maart 2024

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V.,...
29 februari 2024

Gilde Healthcare co-leads oversubscribed €54 Million Series B round of Argá Medtech

Argá Medtech, a company developing a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation (AF), announced it closed a €54M oversubscribed Series B raise co-led by Gilde Healthcare with existing investors, Advent...
28 februari 2024